vs
DORCHESTER MINERALS, L.P.（DMLP）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
DORCHESTER MINERALS, L.P.的季度营收约是REGENXBIO Inc.的1.4倍（$41.9M vs $30.3M），DORCHESTER MINERALS, L.P.净利率更高（38.7% vs -221.3%，领先260.0%），REGENXBIO Inc.同比增速更快（43.0% vs 5.4%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 16.2%）
多切斯特矿业有限合伙是一家总部位于美国的上市有限合伙企业，主要收购、持有及管理油气相关的特许权权益、净利润权益、矿产产权等多元化资产组合，资产覆盖美国多个核心陆上油气产区，为合伙份额持有人提供稳定的现金流回报。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
DMLP vs RGNX — 直观对比
营收规模更大
DMLP
是对方的1.4倍
$30.3M
营收增速更快
RGNX
高出37.6%
5.4%
净利率更高
DMLP
高出260.0%
-221.3%
两年增速更快
RGNX
近两年复合增速
16.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.9M | $30.3M |
| 净利润 | $16.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 38.7% | -221.3% |
| 营收同比 | 5.4% | 43.0% |
| 净利润同比 | 13.7% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DMLPRGNX
| Q4 25 | $41.9M | $30.3M | ||
| Q3 25 | $35.4M | $29.7M | ||
| Q2 25 | $32.4M | $21.4M | ||
| Q1 25 | $43.2M | $89.0M | ||
| Q4 24 | $39.7M | $21.2M | ||
| Q3 24 | $53.5M | $24.2M | ||
| Q2 24 | $37.4M | $22.3M | ||
| Q1 24 | $31.0M | $15.6M |
净利润DMLPRGNX
| Q4 25 | $16.2M | $-67.1M | ||
| Q3 25 | $11.2M | $-61.9M | ||
| Q2 25 | $12.3M | $-70.9M | ||
| Q1 25 | $17.6M | $6.1M | ||
| Q4 24 | $14.2M | $-51.2M | ||
| Q3 24 | $36.4M | $-59.6M | ||
| Q2 24 | $23.6M | $-53.0M | ||
| Q1 24 | $18.2M | $-63.3M |
毛利率DMLPRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率DMLPRGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | — | -176.3% | ||
| Q2 25 | — | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | — | -256.6% | ||
| Q2 24 | — | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率DMLPRGNX
| Q4 25 | 38.7% | -221.3% | ||
| Q3 25 | 31.5% | -208.3% | ||
| Q2 25 | 38.1% | -331.8% | ||
| Q1 25 | 40.9% | 6.8% | ||
| Q4 24 | 35.9% | -241.3% | ||
| Q3 24 | 68.1% | -246.3% | ||
| Q2 24 | 63.2% | -237.7% | ||
| Q1 24 | 58.6% | -405.4% |
每股收益（稀释后）DMLPRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.9M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $102.7M |
| 总资产 | $309.6M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DMLPRGNX
| Q4 25 | $41.9M | $230.1M | ||
| Q3 25 | $41.6M | $274.2M | ||
| Q2 25 | $36.5M | $323.3M | ||
| Q1 25 | $41.5M | $267.9M | ||
| Q4 24 | $42.5M | $234.7M | ||
| Q3 24 | $56.5M | $255.5M | ||
| Q2 24 | $35.2M | $290.4M | ||
| Q1 24 | $37.7M | $338.7M |
股东权益DMLPRGNX
| Q4 25 | — | $102.7M | ||
| Q3 25 | — | $161.5M | ||
| Q2 25 | — | $213.7M | ||
| Q1 25 | — | $274.2M | ||
| Q4 24 | — | $259.7M | ||
| Q3 24 | — | $301.4M | ||
| Q2 24 | — | $348.3M | ||
| Q1 24 | — | $390.7M |
总资产DMLPRGNX
| Q4 25 | $309.6M | $453.0M | ||
| Q3 25 | $330.4M | $525.2M | ||
| Q2 25 | $325.6M | $581.0M | ||
| Q1 25 | $349.0M | $490.9M | ||
| Q4 24 | $366.8M | $466.0M | ||
| Q3 24 | $403.4M | $519.1M | ||
| Q2 24 | $176.0M | $569.4M | ||
| Q1 24 | $184.8M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $34.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | 2.12× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流DMLPRGNX
| Q4 25 | $34.3M | $-52.3M | ||
| Q3 25 | $34.3M | $-56.0M | ||
| Q2 25 | $30.5M | $-49.3M | ||
| Q1 25 | $33.4M | $33.6M | ||
| Q4 24 | $31.5M | $-31.6M | ||
| Q3 24 | $43.7M | $-40.5M | ||
| Q2 24 | $29.4M | $-45.5M | ||
| Q1 24 | $28.0M | $-55.5M |
自由现金流DMLPRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率DMLPRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度DMLPRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率DMLPRGNX
| Q4 25 | 2.12× | — | ||
| Q3 25 | 3.07× | — | ||
| Q2 25 | 2.47× | — | ||
| Q1 25 | 1.89× | 5.53× | ||
| Q4 24 | 2.21× | — | ||
| Q3 24 | 1.20× | — | ||
| Q2 24 | 1.25× | — | ||
| Q1 24 | 1.54× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DMLP
| Royalties | $34.0M | 81% |
| Other | $7.8M | 19% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
